- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 8 - Treatment's Financial Constraints
The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.
The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.
Dr Sugarbaker says of the 4 major cancers ̶ including lung, breast, colon and prostate ̶ lung cancer is by far the number one killer, especially in women. For NSCLC, conversations between providers and payers need to focus on where multi-modality treatment makes sense for certain patients.
Dr Langer comments that increasingly, insurers will approve 1 maintenance drug or another, but not 2. This is largely driven by cost concerns. Even will oral agents, costs are still exorbitant. It can be difficult to find or offer financial support for patients.
Dr Sugarbaker adds that the progress that is been made in NSCLC depends on treatment. “You can’t evaluate new therapies without coverage for particularly protocol therapies.” He says the “onus” is on insurers and managed care organizations to continue supporting innovative therapies in a protocol setting because that is how they have made and will continue to make progress.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More
